S-1: GT Biopharma Registers 14.5M Shares for Resale

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 14.59 million common shares by selling stockholders, stemming from recent private placements and advisory agreements.

Summary

• GT Biopharma, a clinical-stage biopharmaceutical company focused on immuno-oncology, filed an S-1 registration statement for the resale of up to 14,589,546 shares of its common stock by existing selling stockholders.
• The shares include 7,219,771 shares convertible from Series L 10% Convertible Preferred Stock, 7,219,775 shares from vested warrants, and 150,000 shares from pre-funded warrants issued to PDPC Advisors Inc. for advisory services.
• The company will not receive any direct proceeds from the sale of these shares by the selling stockholders.
• Gross proceeds of $3.0 million were received from the exercise of Greenshoe Rights related to a May 2025 private placement, intended for working capital and general corporate purposes.
• As of October 23, 2025, there were 10,636,135 shares of Common Stock outstanding, with an additional 59,010,394 shares underlying outstanding warrants and 597,550 shares underlying outstanding options.
• The company's common stock closed at $0.73 per share on Nasdaq on October 23, 2025.
• Management and the independent auditor have raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash resources to fund operations for one year from December 31, 2024.

Sentiment

Score: 3

Explanation: The filing highlights significant financial challenges, including substantial doubt about the company's ability to continue as a going concern, despite recent capital raises and promising preclinical data. The dilution risk and penny stock classification further contribute to a negative sentiment.

Positives

• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement as of June 13, 2025, after previously receiving a non-compliance notice.
• Successfully raised $3.0 million in gross proceeds from the exercise of Greenshoe Rights, providing capital for working capital and general corporate purposes.
• Proprietary TriKE and Dual Targeting TriKE platforms are designed to harness and enhance natural killer cells for immuno-oncology, with potential for broader applications in hematologic malignancies, solid tumors, and autoimmune disorders.
• Preclinical data suggests TriKE platforms may offer a safer profile than T-cell immunotherapy, with less cytokine release syndrome and fewer neurological complications.

Negatives

• The company has raised substantial doubt about its ability to continue as a going concern, with existing cash resources insufficient to fund anticipated operations for one year from December 31, 2024.
• The independent registered public accounting firm also raised substantial doubt about the company's ability to continue as a going concern in its report on the December 31, 2024 financial statements.
• The company will not receive any proceeds from the sale of the 14,589,546 shares offered by the selling stockholders, limiting direct capital infusion from this specific registration.
• The issuance of shares upon exercise of outstanding warrants (59,010,394 shares) and options (597,550 shares) will have a significant dilutive effect on current stockholders' ownership.
• The common stock may be deemed a low-priced penny stock, which could restrict trading and affect liquidity and market price.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, meaning any return on investment relies solely on stock price appreciation.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient existing cash resources to fund anticipated operations for one year from December 31, 2024.
• There is no assurance that an active and liquid public market for the common stock will develop or be sustained, leading to potential price volatility and difficulty in selling shares.
• The significant number of outstanding warrants (59,010,394 shares) and options (597,550 shares) could lead to substantial dilution for current stockholders upon exercise.
• The common stock may be deemed a low-priced penny stock, subjecting it to specific rules that can restrict trading by broker-dealers and depress the share price.
• There is a risk of future delisting from Nasdaq if the company fails to maintain compliance with listing requirements, which would adversely affect liquidity and market price.
• The company will need additional capital to fund its operations and product development, and there is no assurance that such financing will be available on acceptable terms or at all, potentially delaying or eliminating research programs.
• Anti-takeover provisions in Delaware law, the company's Charter, and Bylaws could discourage, delay, or prevent a third party from acquiring the company, potentially causing the stock price to decline.
• Limited research coverage by securities or industry analysts could negatively affect the trading price and volume of the common stock.

Future Outlook

The company anticipates retaining future earnings for business development and expansion and does not expect to pay cash dividends. It will need substantial additional capital for product development and commercialization, with the timing and degree of future capital requirements depending on scientific and clinical progress, regulatory approvals, and intellectual property costs. There is no assurance that additional financing will be available on acceptable terms or at all.

Management Comments

• "We believe our TriKE and Dual Targeting TriKE platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications."
• "Our preclinical data suggests that this is explained by the TriKE dependent CD16 directed IL-15 proliferation of NK cells but little effect on endogenous T cells."
• "We are using our TriKE platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, solid tumors, and potentially autoimmune disorders."
• "We believe our TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies."

Industry Context

GT Biopharma operates in the highly competitive and capital-intensive immuno-oncology sector, focusing on novel immune cell engager technologies (TriKE and Dual Targeting TriKE). The company's approach of harnessing natural killer cells for cancer treatment positions it within a growing area of immunotherapy, distinct from T-cell therapies by potentially offering a safer profile with less cytokine release syndrome and neurological complications. The need for substantial additional capital is typical for clinical-stage biopharmaceutical companies advancing product candidates through development and regulatory approval.

Comparison to Industry Standards

• The company's focus on Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms represents a specific niche within the broader immuno-oncology field.
• The claim that TriKE platforms are 'potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications' suggests a differentiation strategy against established or developing T-cell therapies (e.g., CAR-T therapies from companies like Novartis, Gilead, or Bristol Myers Squibb) which are known for these side effects. However, no specific comparative clinical data or benchmarks against these companies' products are provided in the filing.
• The collaboration with the Masonic Cancer Center at the University of Minnesota and Dr. Jeffrey Miller, a recognized key opinion leader in NK cell and IL-15 biology, aligns with industry standards for early-stage biopharma companies leveraging academic research and expert guidance.
• The need for significant additional capital to fund operations and product development is standard for clinical-stage biopharmaceutical companies, which typically incur substantial R&D expenses before generating revenue.

Corporate Governance

Related Party Transactions

• Pre-Funded Warrants were issued to PDPC Advisors Inc. for advisory services. Paul Kessler, manager of Bristol Capital Advisors, LLC (investment advisor to Bristol Investment Fund, Ltd.) and CEO of PDPC, has voting and investment control over securities held by PDPC and Bristol Investment Fund Ltd.
• Bristol Investment Fund Ltd. and Five Narrow Lane, L.P. are listed as Selling Stockholders and were involved in the May 2025 private placement and Greenshoe Rights. Paul Kessler has voting and investment control over securities held by BIF, Bristol, Hailstone, and PDPC. Arie Rabinowitz and Joseph Hammer have investment discretion and voting power over shares held by Five Narrow Lane, L.P.

Stakeholder Impact

• Shareholders will experience significant dilution from the exercise of outstanding warrants and options, potentially reducing the value of their holdings.
• The 'going concern' risk poses a substantial threat to the value of shareholder investments and the company's long-term viability.
• The potential for the stock to be deemed a 'penny stock' could limit liquidity and depress prices, making it harder for shareholders to sell their shares.
• Anti-takeover provisions may limit opportunities for shareholders to benefit from premium acquisition offers.
• Employees face potential job insecurity and uncertainty regarding future compensation due to the company's 'going concern' status.
• Creditors face increased risk of non-payment or delayed payment of obligations given the company's stated financial condition and liquidity concerns.

Next Steps

• Continue to advance TriKE and Dual Targeting TriKE platforms into clinical development.
• Seek additional financing to fund operations and product development.
• Maintain compliance with Nasdaq's continued listing requirements to avoid delisting.
• Potentially pursue strategic collaborations for drug candidates.
• File further amendments to the registration statement as necessary to delay its effective date or allow it to become effective.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, as highlighted by both management and its independent auditor. This fundamental financial instability, coupled with significant potential dilution from outstanding warrants and options, and the risk of being classified as a penny stock, presents a high-risk investment profile. While the company has promising technology and recently raised some capital, the severe liquidity concerns and lack of a clear path to sustained operations outweigh any potential upside for a seasoned investor. The company will not receive proceeds from the current resale offering, further emphasizing its ongoing need for capital.

Keywords

GT Biopharma, S-1 Registration, Common Stock, Resale Offering, Warrants, Preferred Stock, Private Placement, Immuno-oncology, TriKE, Biopharmaceutical, Nasdaq, Going Concern, Dilution, PDPC Advisors